Jones David Scott's Insider Trades & SAST Disclosures
Jones David Scott's most recent trade in EyePoint Pharmaceuticals Inc was a trade of 5,000 Common Stock done . Disclosure was reported to the exchange on Feb. 9, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Jones David Scott.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 48,572 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 5,000 | 5,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 43,572 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 4,967 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,955 | 46,617 (0%) | 0% | 28.8 | 56,304 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 28.80 per share. | 09 Feb 2024 | 1,701 | 44,916 (0%) | 0% | 28.8 | 48,989 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 02 Feb 2024 | 209 | 38,171 (0%) | 0% | 11.5 | 2,397 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 28.49 per share. | 02 Feb 2024 | 209 | 37,962 (0%) | 0% | 28.5 | 5,954 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Feb 2024 | 209 | 4,375 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.45 per share. | 26 Jan 2024 | 16,413 | 47,566 (0%) | 0% | 25.4 | 417,653 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 26 Jan 2024 | 16,413 | 63,979 (0%) | 0% | 3.3 | 53,506 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 16,413 | 68,742 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 26 Jan 2024 | 9,604 | 47,566 (0%) | 0% | 12.9 | 123,892 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.27 per share. | 26 Jan 2024 | 9,604 | 37,962 (0%) | 0% | 25.3 | 242,717 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 9,604 | 8,721 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 5,700 | 49,262 (0%) | 0% | 3.3 | 18,582 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,700 | 43,562 (0%) | 0% | 25.0 | 142,554 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 5,700 | 85,455 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 5,600 | 18,625 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jan 2024 | 5,600 | 37,962 (0%) | 0% | 25.0 | 140,068 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 5,600 | 43,562 (0%) | 0% | 12.9 | 72,240 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 300 | 85,155 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 25 | 7,500 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Jan 2024 | 300 | 18,325 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 24 Jan 2024 | 300 | 37,962 (0%) | 0% | 25 | 7,500 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 24 Jan 2024 | 300 | 38,262 (0%) | 0% | 12.9 | 3,870 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 24 Jan 2024 | 300 | 38,562 (0%) | 0% | 3.3 | 978 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.69 per share. | 22 Jan 2024 | 28,750 | 37,962 (0%) | 0% | 22.7 | 652,254 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 28,750 | 31,250 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.13 per share. | 22 Jan 2024 | 28,750 | 66,712 (0%) | 0% | 10.1 | 291,238 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones Scott David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.47 per share. | 22 Jan 2024 | 5,416 | 72,128 (0%) | 0% | 11.5 | 62,122 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 5,416 | 4,584 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 22.24 per share. | 22 Jan 2024 | 5,416 | 66,712 (0%) | 0% | 22.2 | 120,437 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 500 | 37,962 (0%) | 0% | 25 | 12,500 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.26 per share. | 22 Jan 2024 | 500 | 38,862 (0%) | 0% | 3.3 | 1,630 | Common Stock |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 500 | 91,155 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Scott David Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.90 per share. | 22 Jan 2024 | 400 | 38,362 (0%) | 0% | 12.9 | 5,160 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2024 | 400 | 24,225 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 25.00 per share. | 22 Jan 2024 | 400 | 38,462 (0%) | 0% | 25 | 10,000 | Common Stock |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 42,000 | 42,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2024 | 21,000 | 21,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Scott Jones David | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 30,570 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | Jones David Scott | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Jan 2024 | 15,285 | 42,109 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Jones Scott | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 20.40 per share. | 05 Jan 2024 | 4,147 | 37,962 (0%) | 0% | 20.4 | 84,599 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2023 | 45,855 | 45,855 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,000 | 28,089 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 5,000 | 10,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 4,967 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2023 | 4,967 | 23,089 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,483 | 26,606 (0%) | 0% | 4.2 | 6,184 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.17 per share. | 09 Feb 2023 | 1,473 | 25,133 (0%) | 0% | 4.2 | 6,142 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2023 | 91,655 | 91,655 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 16,729 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 4,105 | 0 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.95 per share. | 28 Feb 2022 | 1,130 | 15,599 (0%) | 0% | 10.0 | 11,244 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 60,000 | 60,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2022 | 15,000 | 15,000 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 9,934 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2022 | 4,966 | 14,097 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.13 per share. | 09 Feb 2022 | 1,473 | 12,624 (0%) | 0% | 10.1 | 14,921 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Nov 2021 | 10,000 | 10,000 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 60,300 | 60,300 | - | - | Stock Option (Right to Buy) | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2021 | 14,900 | 19,005 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,105 | 9,082 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 4,105 | 4,105 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 10.81 per share. | 28 Feb 2021 | 1,702 | 7,380 (0%) | 0% | 10.8 | 18,399 | Common Stock |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 41,050 | 82,100 | - | - | Restricted Stock Units | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2020 | 41,050 | 41,050 (0%) | 0% | 0 | Common Stock | |
| EyePoint Pharmaceuticals Inc | David Scott Jones | SVP & Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.76 per share. | 30 Jun 2020 | 14,060 | 26,990 (0%) | 0% | 0.8 | 10,643 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges